XILAPAK

Manufacturer
SOLUTECH PHARMACEUTICALS LLC
Effective date
2017-11-02
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:24:44

Label at a glance#

ProductXILAPAK
Active ingredientFLUOCINOLONE ACETONIDE
Label structure32 sections

Indications and uses

Fluocinolone Acetonide Topical Solution is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Dosage and administration

Apply Cetaphil Cleanser to the affected area, rub gently and rinse with water. Then apply Fluocinolone Acetonide 0.01% Topical Solution and rub into skin until absorbed. Apply twice a day or as directed by your physician. Cover the affected area with silicone tape at bedtime or as directed by your physician.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

(NDC 70350-5218-1)

For external use only.
Not for ophthalmic use.

Rx Only

XILAPAK KIT DESCRIPTION

DESCRIPTION SECTION

XILAPAK is supplied as 3 components in a kit:

  • FLUOCINOLONE ACETONIDE TOPICAL SOLUTION USP, 0.01% (NDC 52565-012-59), 60mL
  • CETAPHIL CLEANSER (NDC 00299-3921-40), 4 fl oz
  • SILICONE TAPE, 1 Roll, 5.5 yards

INDICATION AND USAGE

INDICATIONS & USAGE SECTION

For the management of hypertrophic tissues, keloid tissues, dermatitis and dermatoses.1

1 This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent disease.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Apply Cetaphil Cleanser to the affected area, rub gently and rinse with water. Then apply Fluocinolone Acetonide 0.01% Topical Solution and rub into skin until absorbed. Apply twice a day or as directed by your physician. Cover the affected area with silicone tape at bedtime or as directed by your physician.

WARNINGS

WARNINGS SECTION

FOR EXTERNAL USE ONLY. Avoid contact with eyes, lips or mucous membranes. Do not use on areas of broken skin.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Do not use if known hypersensitivity to any of the listed ingredients of any of the components included in the kit.

PRECAUTIONS

PRECAUTIONS SECTION

Stop use and ask a doctor if redness or irritation develops. Keep this and all other medications out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

PREGNANCY

PREGNANCY SECTION

If pregnant or breast feeding, ask a health professional before use.

HOW SUPPLIED SECTION

STORAGE AND HANDLING SECTION

Store at 20°-25°C (68° to 77°F); Keep away from heat and flame. Protect from freezing. [See USP Controlled Room Temperature.]

SPL UNCLASSIFIED SECTION

MANUFACTURED FOR:
SOLUTECH PHARMACEUTICALS LLC
PEORIA, AZ 85345

Rx Only

SPL UNCLASSIFIED SECTION

Fluocinolone Acetonide Topical Solution USP, 0.01%

Rx Only

DESCRIPTION

DESCRIPTION SECTION

Fluocinolone Acetonide Topical Solution USP, 0.01% is intended for topical administration. The active component is the corticosteroid fluocinolone acetonide, which has the chemical name pregna-1,4-diene-3,20-dione,6,9-difluoro-11,21-dihydroxy16,17[(methylethylidene)bis(oxy)]-, (6α,11β,16α)-. It has the following chemical structure:

Chemical StructureChemical Structure

Fluocinolone Acetonide Solution USP contains fluocinolone acetonide 0.1 mg/mL in a water-washable base of citric acid and propylene glycol.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions.

The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

Pharmacokinetics

PHARMACOKINETICS SECTION

The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase the percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (See DOSAGE AND ADMINISTRATION).

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Fluocinolone Acetonide Topical Solution is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of components of the preparation.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glycosuria in some patients.

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Children may absorb proportionally larger amounts of topical-corticosteroids and thus be more susceptible to systemic toxicity (See PRECAUTIONS – Pediatric Use).

If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

As with any topical corticosteroid product, prolonged use may produce atrophy of the skin and subcutaneous tissues. When used on intertriginous or flexor areas, or on the face, this may occur even with short-term use.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

Information for the Patient

INFORMATION FOR PATIENTS SECTION

Patients using topical corticosteroids should receive the following information and instructions:

  1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
  2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
  3. The treated skin area should not be bandaged or otherwise covered or wrapped so as to be occlusive unless directed by the physician.
  4. Patients should report any signs of local adverse reactions especially under occlusive dressing.
  5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.

Laboratory Tests

LABORATORY TESTS SECTION

The following tests may be helpful in evaluating HPA axis suppression:

Urinary free cortisol test
ACTH stimulation test

Carcinogenesis, Mutagenesis and Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.

Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

Pregnancy Category C

PREGNANCY SECTION

Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.

Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:

Burning
Itching
Irritation
Dryness
Folliculitis
Hypertrichosis
Acneiform eruptions
Hypopigmentation
Perioral dermatitis
Allergic contact dermatitis
Maceration of the skin
Secondary infection
Skin atrophy
Striae
Miliaria

OVERDOSAGE

OVERDOSAGE SECTION

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS).

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Fluocinolone Acetonide Topical Solution is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion.

Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions.

If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

HOW SUPPLIED

HOW SUPPLIED SECTION

Fluocinolone Acetonide Topical Solution 0.01%
60 mL Bottle with applicator tip - NDC 52565-012-59

STORAGE

STORAGE AND HANDLING SECTION

Store at room temperature 15° to 25°C (59° to 77°F); avoid freezing and excessive heat above 40°C (104°F).

SPL UNCLASSIFIED SECTION

Teligent Pharma, Inc.
Buena, New Jersey 08310
PI012
Iss. 11/12

SPL UNCLASSIFIED SECTION

Cetaphil Cleanser 4 fl oz

Galderma Laboratories, L.P.

Product details

DESCRIPTION SECTION

For All Skin Types

  • Mild, non-irritating formula
  • Softens as it cleans
  • Non-comedogenic/fragrance free
  • Dermatologist recommended

This gentle, soap-free cleanser was originally formulated for dermatologists, specifically for everyday cleansing of even the most sensitive skin.

  • Soothing, non-irritating cleanser ideal for face, hands and body
  • Helps skin retain needed moisture
  • Rinses easily and leaves skin feeling soft, smooth and healthy

Ingredients: Water, Cetyl Alcohol, Propylene Glycol, Sodium Lauryl Sulfate, Stearyl Alcohol, Methylparaben, Propylparaben, Butylparaben

Cetaphil Cleanser is easy to use:

Directions for use with water: Apply cleanser and gently massage into skin. Rinse.

Directions for use without Water: Apply a liberal amount to the skin and rub gently. Remove excess with a soft cloth, leaving a thin film of CETAPHIL on the skin.

Warnings

WARNINGS SECTION

For external use only.

Ask a doctor or pharmacist if it is safe for you to use this medicine if you have:

  • Deep wounds or open sores;
  • Swelling, warmth, redness, oozing, or bleeding on the site of application;
  • Large areas of skin irritation;
  • Any type of allergy; or
  • If you are pregnant or breast-feeding.

Contraindications

CONTRAINDICATIONS SECTION

Contraindicated in patients with known hypersensitivity to any of the listed ingredients.

Side Effects

SPL UNCLASSIFIED SECTION

No common side effects have been reported with this product. Stop use and ask a doctor if rash occurs.

SPL UNCLASSIFIED SECTION

Silicone Tape, 1 Roll, 5.5 yards

Description

DESCRIPTION SECTION

Silicone tape is a silicone blended tape. This tape is designed to not harm the skin when it is being removed. Most tapes pull the skin and the small hairs, causing unnecessary damage. This Silicone tape has a paper blended backing that allows a gentle, but strong adhesion to the skin that remains constant. Most tapes increase their adhesion over time, which increases the damage when they are removed.

The silicone tape can be re-positioned without losing any of its tacky qualities. The gentle adhesion does not lower the quality of the hold either. This tape is adhesive enough that it can be worn in the shower without losing effectiveness.

Purpose

SPL UNCLASSIFIED SECTION

For alleviating tension on the scar and its surrounding skin. Tension on a wound and scar is known to increase scar tissue formation.

Because of its adherence, silicone tape reduces tension (e.g. tear and stretch) along the incision line or wound which is known to minimize the degree of scarring in terms of spreading or thickening.

Warnings

WARNINGS SECTION

FOR EXTERNAL USE ONLY. Avoid contact with eyes, lips or mucous membranes. Do not use on areas of broken skin. Do not use if you have known hypersensitivity to silicone

Precautions

PRECAUTIONS SECTION

Stop use and ask a doctor if redness or irritation or rash develops. Keep out of reach of children.

Directions

DOSAGE & ADMINISTRATION SECTION

Apply to the affected area as directed by your physician.

PRINCIPAL DISPLAY PANEL - Kit Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Solutech
PHARMACEUTICALS

XILAPAK KIT

NDC 70350-5218-1

RX ONLY

PRINCIPAL DISPLAY PANEL - Kit Carton
PRINCIPAL DISPLAY PANEL - Kit Carton

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1191310fluocinolone acetonide 0.01 % Topical SolutionPSN1
1191310fluocinolone acetonide 0.1 MG/ML Topical SolutionSCD1
1191310fluocinolone acetonide 0.01 % Topical SolutionSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
FLUOCINOLONE ACETONIDE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
0adb2af5-1ecf-4df5-912b-16ae89228294Product name620240829
65f6255d-41cc-425f-ba54-b1bea4947886Product name520210930
5ba208e4-886f-44da-e218-ab4f4cad2c49Product name520190612
e5a2793f-318b-72fd-b734-c44ecc6f6748Product name220190213
9e453f34-aacb-44d5-a119-c0e3dc1fca2aProduct name120160622
7df2570a-c555-4d82-9189-9247c722b62cProduct name120150402
85490a6b-2306-6bf2-c51b-eb63537dc2daProduct name120140508
a78a3633-fd06-b0af-63b3-c714de3b3bfaProduct name120140508
b2d0a9c2-fd0c-a9b4-ae41-f6a4eef4fbf6Product name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
70350-5218-12020-01-31C16284748780-19d75b9d0-f313-f424-e053-dadaa90a57ceXILAPAK KIT

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
52565-012-59XILAPAK60 mL in 1 BOTTLE, WITH APPLICATORSOLUTION60 mL0.1 mg in 1mL1
52565-012-59XILAPAK1 in 1 CARTONSOLUTION0.1 mg in 1mL1
70350-5218-1XILAPAK1 in 1 CARTONKIT11

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0299-3921XILAPAK (FLUOCINOLONE ACETONIDE) KIT [SOLUTECH PHARMACEUTICALS LLC]1Unmatched20171104_f1b8a26a-dc63-4701-8a78-cc1f99fca1b3.zip
52565-012XILAPAK (FLUOCINOLONE ACETONIDE) KIT [SOLUTECH PHARMACEUTICALS LLC]1Legacy NDC20171104_f1b8a26a-dc63-4701-8a78-cc1f99fca1b3.zip
70350-5218XILAPAK (FLUOCINOLONE ACETONIDE) KIT [SOLUTECH PHARMACEUTICALS LLC]1Legacy NDC, 3 package rows20171104_f1b8a26a-dc63-4701-8a78-cc1f99fca1b3.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
70350-5218-1EA - Each70350-52188e5d0513-a89c-4d47-b7af-ee920dd1b2c112017-11-06
52565-012-59ML - Milliliter52565-012e73c8061-3edf-4c0e-93f3-e4144c8853bc12013-02-13

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 12 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
70350-521870350-5218-1
52565-01252565-012-59
0299-39210299-3921-40

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 11 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N015296-001SYNALARFLUOCINOLONE ACETONIDE0.01%SOLUTION / TOPICALATRLD, RS, Approved before 1982

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
N015296-001AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 198284e616aacf4f…
2026-08-18 06:07:402026-07N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 1982caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 1982011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 198231067a03dcf5…
2025-08-23 18:47 UTC2025-08N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 19826a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 1982fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 1982b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 198203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 19822680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 19825bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 1982d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 1982d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 198279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 1982301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 19821e350fbaab3a…
2024-05-31 18:47 UTC2024-05N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 19828072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 19825c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 19825d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 19824b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 198274a2ff9319b5…
2022-03-09 01:35 UTC2022-03N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 1982bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 1982782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 198287673890dc5c…
2021-03-12 10:30 UTC2021-03N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 19825aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 19828869cabd3fbd…
2020-11-12 02:37 UTC2020-11N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 1982c0c555d07b60…
2019-12-14 00:12 UTC2019-12N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 19823f01610625f2…
2019-09-15 20:21 UTC2019-09N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 1982b00525d2431f…
2019-07-19 19:46 UTC2019-07N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 1982ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 19826a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 19821c564ffb4f44…
2023-12-20 04:57 UTC2023-12N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 1982ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 1982a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 19829b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 1982a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 19823f0d92c62455…
2023-05-13 08:27 UTC2023-05N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 1982053a50430f4f…
2023-01-26 05:58 UTC2023-01N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 19823bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 19823a93d1ddd44b…
2022-10-28 04:53 UTC2022-10N015296-001SYNALAR0.01%SOLUTION / TOPICALATRLD, RS, Approved before 1982f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08N015296-001AT184e616aacf4f…
2026-08-18 06:07:402026-07N015296-001AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N015296-001AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N015296-001AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08N015296-001AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N015296-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N015296-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N015296-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N015296-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N015296-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N015296-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N015296-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N015296-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N015296-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N015296-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05N015296-001AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N015296-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N015296-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N015296-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N015296-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03N015296-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N015296-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N015296-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03N015296-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N015296-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11N015296-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12N015296-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09N015296-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07N015296-001AT1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N015296-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N015296-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12N015296-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N015296-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N015296-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N015296-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N015296-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05N015296-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01N015296-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N015296-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10N015296-001AT1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
1bdd2cf2-169b-4e44-a01b-122ee5661ae8f1b8a26a-dc63-4701-8a78-cc1f99fca1b32017-11-02Warnings, Adverse reactionsExact identifier
spl id: 1bdd2cf2-169b-4e44-a01b-122ee5661ae8
spl set id: f1b8a26a-dc63-4701-8a78-cc1f99fca1b3

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.